Sectors
INBX
Inhibrx Biosciences, Inc.
125.64
2 x 90.79
1 x 156.64
bid
ask
+
2.23
1.81%
03:06 PM
timesize
| Ytd | 59.04% | |
| 1y | 345.53% |
121.59
day range
127.13
26.19
52 week range
155.29
| Open | 123.39 | Prev Close | 123.41 | Low | 121.59 | High | 127.13 | Mkt Cap | 1.85B |
| Vol | 238.74K | Avg Vol | 300.25K | EPS | -8.87 | P/E | N/A | Forward P/E | -14.09 |
| Beta | 3.51 | Short Ratio | 14.27 | Inst. Own | 91.07% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-13 | 50-d Avg | 94.19 | 200-d Avg | 87.78 | 1yr Est | 266.67 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-13 | 2026-09 | -2.45 | N/A | N/A | N/A |
| 2026-08-13 | 2026-06 | -2.28 | -2.34 | -0.06 | -2.63% |
| 2026-05-14 | 2026-03 | -2.37 | -2.15 | 0.22 | 9.28% |
| 2026-03-19 | 2025-12 | -2.08 | -2.11 | -0.03 | -1.44% |
| 2025-11-14 | 2025-09 | -2.08 | -2.28 | -0.2 | -9.62% |
| 2025-08-13 | 2025-06 | -2.92 | -1.85 | 1.07 | 36.64% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-24 | HC Wainwright & Co. | Upgrade | Buy | |
| 2026-04-08 | Stifel | Upgrade | Buy | |
| 2025-08-22 | JMP Securities | Upgrade | Market Perform | Market Perform |
| 2025-05-15 | JMP Securities | Upgrade | Market Perform | Market Perform |
| 2025-03-18 | Citizens Capital Markets | Upgrade | Market Perform | Market Perform |
| 2025-01-22 | JMP Securities | Upgrade | Market Perform | Market Perform |
Profile
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-03-26 | KAYYEM JON FAIZ | Director | 0.00 | Stock Gift |
| 2024-09-15 | LAPPE MARK | Chief Executive Officer | 0.00 | Purchase |
| 2025-10-06 | VIKING GLOBAL INVESTORS LP | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2024-10-02 | VUORI KRISTIINA S. | Director | 20.44K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Morgan Stanley | 1.31M | 161.43M | 8.89% |
| 2026-06-29 | Perceptive Advisors Llc | 1.30M | 160.16M | 8.82% |
| 2026-06-29 | Sanofi | 1.16M | 142.90M | 7.87% |
| 2026-06-29 | Viking Global Investors, L.P. | 1.12M | 138.70M | 7.64% |
| 2026-06-29 | HighTower Advisors, LLC | 870.55K | 107.43M | 5.92% |
| 2026-06-29 | Bank of America Corporation | 841.14K | 103.81M | 5.72% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 399.55K | 49.31M | 2.71% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 363.84K | 44.90M | 2.47% |
| 2026-06-29 | SmallCap World Fund Inc | 353.29K | 43.60M | 2.40% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 244.12K | 30.13M | 1.66% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 108.78K | 13.42M | 0.74% |
| 2026-05-30 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 90.13K | 11.12M | 0.61% |
Dividend
| Dividend | Date |
|---|---|
| 0.85 | 2024-05-30 |